TG Therapeutics, Inc. reported significant financial growth for the fiscal year ending December 31, 2025, with total revenue reaching approximately $616.3 million, a substantial increase from $329.0 million in 2024. This growth was primarily driven by net product sales of BRIUMVI (ublituximab-xiiy), which amounted to $606.9 million, compared to $313.7 million in the previous year. The company also noted a rise in sales to its ex-U.S. licensing partner, Neuraxpharm, contributing $12.8 million in 2025, up from $3.7 million in 2024. Despite this revenue increase, TG Therapeutics continues to face challenges, with an accumulated deficit of approximately $1.1 billion as of the end of 2025.
The company has made strategic advancements, including the launch of BRIUMVI in the U.S. in January 2023 and a subsequent commercialization agreement with Neuraxpharm in August 2023 for markets outside the U.S. This agreement is valued at up to $645 million, including milestone payments and royalties. Additionally, TG Therapeutics is actively pursuing the development of a subcutaneous formulation of ublituximab and exploring its use in other autoimmune diseases, which reflects the company's strategy to expand its product offerings and market reach.
Operationally, TG Therapeutics has increased its workforce to 399 employees as of February 2026, indicating a commitment to support its growing commercialization efforts. The company is also focused on enhancing its clinical development capabilities, with ongoing trials for both ublituximab and azer-cel, a CAR T-cell therapy for autoimmune diseases. The Phase 3 trial for subcutaneous ublituximab is currently enrolling participants, and the company has reported that it is over 75% enrolled in this pivotal study.
Despite the positive financial performance and strategic developments, TG Therapeutics faces several risks, including reliance on third-party manufacturers for product supply and potential regulatory challenges. The company has acknowledged that its ability to maintain profitability will depend on successful commercialization of BRIUMVI and the timely completion of clinical trials for its product candidates. Looking ahead, TG Therapeutics anticipates continued investment in research and development, which may require additional financing to support its operations and growth initiatives. The company believes that its existing cash reserves, along with projected revenues, will be sufficient to fund operations for at least the next twelve months, but it remains open to raising additional capital as needed.
About TG THERAPEUTICS, INC.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.